| Today’s Big NewsJan 10, 2024 |
|
Tuesday, January 23, 2024 | 11am ET / 8am PT Join a cutting-edge conversation on January 23, 2024 with Real Chemistry and Quid as they explore how their partnership has forged a deeper understanding of patient insights. Register now. 
|
|
| By Max Bayer Sanofi CEO Paul Hudson did not rule out further business development related to Pompe disease despite the FTC's challenge of its deal with Maze Therapeutics. The pharma company's concern is that the latest action could result in the death of the program due to a lack of funding. |
|
|
|
By Zoey Becker In AZ's push to reach industry-leading growth by 2030, confidence is key, Chief Financial Officer Aradhana Sarin said at the J.P. Morgan Healthcare Conference. Besides that goal, the company wants to be a top-3 player in its five disease areas of focus. |
By Andrea Park Despite concerns about ongoing challenges in the healthcare sector and potential declines in the number of patients undergoing certain procedures, Intuitive Surgical had a year to remember. |
By Annalee Armstrong Eli Lilly CEO David Ricks, speaking to the slow and steady progress that brought tirzepitide to the world, says the Indianapolis pharma is now ready to open up the chocolate factory. |
|
Wednesday, January 24, 2024 | 2pm ET / 11am PT Join industry experts to hear how digital collection of patient-reported outcomes (PROs) can lay the foundation for advancing health equity, which methods can ensure that PROs are relevant for diverse populations, and what challenges and opportunities still lie ahead. Register now. 
|
|
By Kevin Dunleavy In his first presentation as the new CEO of BioMarin, Alexander Hardy left no doubt about his mission for the rare and genetic disease specialist. The top priority for the former Genentech CEO is to accelerate and maximize the commercial potential of dwarfism drug Voxzogo. |
By Max Bayer CRISPR Therapeutics board member Simeon George said it's "still early days" for the company's pursuit of new partners, saying more work has to be done on coming to potential deal terms. |
By Annalee Armstrong,Gabrielle Masson,James Waldron,Max Bayer,Ben Adams We're off for another day of the J.P. Morgan Healthcare Conference 2024. The flood of licensing deals and M&A may have slowed, but there's still plenty of action to come as companies make pitches to their peers, investors and industry watchers. |
By Conor Hale Presenting at the J.P. Morgan Healthcare Conference in San Francisco, the company reported about $1.12 billion in revenue from last year’s fourth quarter, representing a gain of 3% over the same period the year before. |
By Zoey Becker,Fraiser Kansteiner,Kevin Dunleavy,Angus Liu,Eric Sagonowsky On Wednesday at the J.P. Morgan Healthcare Conference, attendees had a chance to hear from AbbVie, Amarin and many other pharmaceutical companies. |
By Andrea Park Barely a month after Medtronic announced the European clearance of its rechargeable Percept RC deep brain stimulation system, the device has racked up a stateside approval, too. |
By Kevin Dunleavy Age 37 might be old for a “coming-out party,” but that’s the situation for Alkermes at this year’s J.P. Morgan Healthcare Conference, said chief operating officer Blair Jackson. After the most transformational year the history of the Dublin, Ireland, drugmaker, Alkermes is stripped down and anxious to carry on in its new role as a pure-play neuroscience specialist. |
By Nick Paul Taylor Coherus BioSciences wants to get off the TIGIT rollercoaster. Less than two years after paying $35 million to exercise its option, the biotech has told Junshi Biosciences it is dropping the TIGIT asset CHS-006 from the collaboration. |
By Conor Hale The Varipulse platform for treating intermittent cases of drug-resistant atrial fibrillation—the irregular heartbeat associated with an increased risk of stroke—marks the first and only pulsed-field system approved in the country. |
By James Waldron A total of 45 positions will be impacted, with the changes likely to be completed by the end of the quarter. |
By Andrea Park Perhaps diving headfirst into a New Year’s resolution to put itself out there more, Caris Life Sciences is kicking off 2024 with a pair of new collaborations. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," Fierce Biotech staff writer Gabrielle Masson and senior editor Annalee Armstrong look back at the year in biotech, which was defined by massive layoffs across the industry. They also discuss their favorite stories of the year, including an appearance from a popstar whose reputation precedes her. |
|
|---|
|
|
|
Stability and particle formation are key variables across the lifecycle. New instruments that improve measurement are transforming testing and becoming necessary. Download this essential reading now for biopharma companies that want to understand how particle detection is evolving and the value new technologies provide across the lifecycle. 
|
|
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
eBook This e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development.
Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper The road to digital health innovation is exciting but complex and requires thoughtful navigation; this whitepaper serves as your guide through this process. Sponsored by: S3 Connected Health |
| |
|
